Facts about MSS Can12™

What is the Predisposition Test for Cancers (Can-12)?

The Predisposition Test for Cancers evaluates your lifetime risk of developing 12 prevalent types of cancers. It uses a two-pronged approach, molecular and clinical examinations. Molecular examination involves the scanning of one’s DNA, in search of a panel of 768 SNPs inherited from one’s parents that predispose an individual to either increased or decreased risk of developing cancers. Clinical examination associates one’s lifestyle choices, family history and medical history to cancer risk. The combined clinico-molecular analysis thus provides a more thorough and comprehensive cancer risk assessment than each of the two examinations alone.

The 12 types of cancers are:

  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Gastric cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Nasopharyngeal cancer
  • Oral cancer
  • Ovarian cancer
  • Prostate cancer
  • Thyroid cancer


What is the procedure involved?

A small sample of buccal cells or blood (about 5ml) will be drawn and clinical information will be collected. The procedure is minimally invasive. DNA will be extracted from the blood sample and subjected to Microarray Technology based SNP genotyping. Clinical information will be examined by our panel of physicians.

Who should take this test?

Any individual who has never been diagnosed with any type of cancers will benefit from this test. Any individual who has suffered cancer should also consider ordering the test for yourself, your offspring, and blood relatives for comparative study, in order to ascertain if the same cancer-causing genetic markers have been passed on or shared by your loved ones.


How frequent do I need to go for screening?

The molecular test result represents one’s genetic profile at that time of testing. The probability of your DNA getting mutations at the exact locations of risk-associated SNPs is low within a short span of time. However, your medical doctors may advise you on the need for future screening depending on your risk profile. Has the test been validated? The association of the 768 SNPs with the 12 cancer types has been independently validated at our molecular research laboratory. The risk classification was established according to the comparative study of the genomic profile of cancer patients with that of healthy individuals.